LC
Lineage Cell Therapeutics, Inc.
LCTX · AMEX
$1.02 -0.97% (-$0.01)
1M -4.63%
Market Cap $258.0M
P/E Ratio -
Div. Yield -
ROE 71.14%
Piotroski F-Score Weak
3/9Valuation
24 /100
Expensive P/S 19.72x
P/B 4.24x
P/E N/A
Growth
14 /100
Declining Rev. growth 0.33%
Book val. growth 15.31%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 96.59%
Net margin 246.58%
FCF margin 182.98%
Quality
2 /100
Poor ROIC 23.25%
ROE 71.14%
Asset turnover 0.12x
Debt
100 /100
Low Debt/Equity 0.04x
Current ratio 6.61x
Int. coverage N/A
Stability
8 /100
Unstable Beta 1.55x
Rev. volatility 46.20%
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o LCTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Brian Culley
Employees
75
Headquarters
Carlsbad
Nadchodzące wydarzenia
05 LIS
Earnings
Upcoming earnings report